HIV-1 Reverse Transcriptase Mutation Detection for NNRTI Hypersusceptibility

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current antiviral drugs for HIV, particularly NNRTIs like efavirenz, nevirapine, and delavirdine, face challenges due to the high mutation rate of HIV, leading to rapid emergence of resistant strains, making it difficult to determine hypersusceptibility and effectively treat HIV infections.

Innovation Solution

Detecting specific mutations at codons 65, 69, 70, 184, 215, and others in the HIV-1 reverse transcriptase gene to determine hypersusceptibility to NNRTIs, using methods such as PCR and phenotypic assays like PHENOSENSE™ to assess drug susceptibility and resistance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antiviral drugs like NNRTIs are administered to treat HIV infection, then treatment effectiveness is improved, but HIV mutation rate leads to rapid emergence of resistant strains

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidviral strain susceptibility

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent performs genotypic analysis to detect mutations in the reverse transcriptase gene before initiating NNRTI treatment. By identifying susceptible strains (wild-type or with specific mutations like M184V) in advance, the method enables preliminary selection of appropriate NNRTI therapy, preventing treatment failure due to pre-existing resistance mutations.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent establishes a feedback loop where treatment responses and viral load measurements are continuously monitored. Based on this feedback, the presence or absence of specific mutations correlates with treatment outcomes, allowing clinicians to adjust therapy decisions. The method uses mutation detection results to feedback into treatment selection, ensuring ongoing effectiveness despite viral evolution.

Inventive Principle:

Principle #23Feedback

2Measurement precision

If genotypic analysis methods are used to detect mutations, then identification accuracy is improved, but complexity of detection increases

Engineering Contradiction:

Improvemutation detection accuracyVSAvoiddetection system complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments the complex detection task into focused analysis of specific codons (65, 69, 70, 184, 215) in the reverse transcriptase gene. Rather than sequencing the entire genome, the method concentrates resources on detecting mutations at these predetermined locations known to correlate with NNRTI susceptibility, simplifying the overall detection process while maintaining high accuracy.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses PCR amplification to create multiple copies of the reverse transcriptase gene region containing the mutations of interest. This copying approach allows sensitive detection of minority viral populations and enables subsequent sequencing or probe-based detection methods to work effectively on amplified material rather than directly on low-abundance viral RNA.

Inventive Principle:

Principle #26Copying

Data Source

PatentUS8178291B2Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors

Publication Date: 2012.05.15 MONOGRAM BIOSCIENCES INC

AI summary

This invention relates to methods for determining hypersusceptibility of HIV-1 viruses to non-nucleoside reverse transcriptase inhibitors (NNRTIs) based on the viral genotypes. The methods generally comprise detecting, in a gene encoding reverse transcriptase of the HIV-1, the presence of a mutation at codon 65, 69, or 74 alone or in combination with one or more mutations at certain other codons. Combinations of mutation associated with hypersusceptibility to NNRTIs are also disclosed.